Magenta Therapeutics (MGTA) Highlights Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at EBMT 2021 Meetings

Go back to Magenta Therapeutics (MGTA) Highlights Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at EBMT 2021 Meetings
(NASDAQ: MGTA) Delayed: 10.95 -1.87 (14.59%)
Previous Close $12.82    52 Week High
Open $13.22    52 Week Low
Day High $13.22    P/E N/A 
Day Low $10.40    EPS
Volume 435,039